One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Replimune Group, Inc.
REPL · NMS · Healthcare · Biotechnology
Current price
$20.08
52-week range
$1.50 - $21.26
Market cap
$1.90B
Balance sheet
Healthy
-35.93x Concerning
Net cash $180.64M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Replimune Group, Inc.
Replimune is developing new cancer treatments that use a special virus to train the body's own immune system to fight tumors. Their main source of money will come from selling these approved treatments to hospitals and doctors. This matters because if their treatments work well and get approved, they could help many cancer patients and become a successful company.
How the company got here
Replimune Group was founded in 2015 by a team with deep experience in developing viruses that can fight cancer. The company's core idea was that while earlier attempts at using viruses to treat cancer showed promise, improving the engineering of these viruses could lead to even stronger immune responses against tumors. Replimune went public on the Nasdaq stock exchange in 2018, which provided the capital needed to fund its extensive research and clinical trials. Since then, the company's journey has been focused on advancing its technology from early-stage research into human testing, with its main product candidate, RP1, leading the way.
What it actually does
Replimune develops a type of cancer treatment called oncolytic immunotherapy. This involves using specially engineered viruses that are designed to infect and kill cancer cells directly. As these viruses replicate within the tumor, they also trigger the body's immune system to recognize and attack the cancer. Think of it like using a Trojan horse strategy: the virus gets inside the cancer cell, destroys it, and in the process, alerts the body's own defense forces to the presence of the enemy.
Oncolytic Immunotherapies (RP1, RP2, RP3)
Replimune's main business is developing its oncolytic immunotherapies, which are experimental cancer treatments. The company's lead product candidate is called RP1. It's a modified version of the herpes simplex virus (HSV-1), the virus that causes cold sores, but engineered to specifically target and replicate within cancer cells. RP1 is designed to kill tumor cells and also to express a protein that helps stimulate the immune system. Replimune is also developing other similar therapies, RP2 and RP3, which build upon the same underlying technology but are designed with additional features to further enhance the immune response against cancer. These therapies are being tested in clinical trials for various types of solid tumors, often in combination with other cancer treatments like immune checkpoint inhibitors.
What management is betting on now
Replimune's main strategy is to prove that its engineered viruses can significantly improve outcomes for cancer patients, especially those whose cancers haven't responded well to existing treatments like immune checkpoint inhibitors. They are heavily focused on advancing their lead product, RP1, through late-stage clinical trials and seeking regulatory approval. The company is also investing in developing its next-generation therapies, RP2 and RP3, which are built on the same viral platform but with added capabilities. The ultimate goal is to establish these oncolytic immunotherapies as a crucial part of cancer treatment, used either on their own or alongside other therapies.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2025 Q3
$-52.51M
FY2025 Q4
$-54.87M
FY2026 Q1
$-79.76M
FY2026 Q2
$-82.56M
FY2026 Q3
$-66.09M
FY2026 Q4
$-56.17M
FY2027 Q1
$-75.73M
FY2027 Q2
$-47.78M
Revenue
—
Net income
$-57.12M
Diluted EPS
-0.54
Operating cash flow
$-47.70M
Free cash flow
$-47.78M
Fetching…
Sources
Revenue
—
Net income
$-69.77M
Diluted EPS
-0.72
Operating cash flow
$-75.73M
Free cash flow
$-75.73M
Fetching…
Sources
Revenue
—
Net income
$-73.22M
Diluted EPS
-0.76
Operating cash flow
$-56.16M
Free cash flow
$-56.17M
Fetching…
Sources
Revenue
—
Net income
$-70.93M
Diluted EPS
-0.77
Operating cash flow
$-65.95M
Free cash flow
$-66.09M
Fetching…
Sources
Revenue
—
Net income
$-83.10M
Diluted EPS
-0.90
Operating cash flow
$-81.21M
Free cash flow
$-82.56M
Fetching…
Sources
Revenue
—
Net income
$-86.69M
Diluted EPS
-0.95
Operating cash flow
$-77.02M
Free cash flow
$-79.76M
Fetching…
Sources
Revenue
—
Net income
$-74.13M
Diluted EPS
-0.82
Operating cash flow
$-53.73M
Free cash flow
$-54.87M
Fetching…
Sources
Revenue
—
Net income
$-66.34M
Diluted EPS
-0.79
Operating cash flow
$-50.71M
Free cash flow
$-52.51M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $20.08
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $180.6M - more cash than debt. Interest coverage -35.9x.
Net debt
$-180.64M
Interest coverage
-35.93x
Replimune Group, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
REPL
BASELINE
Replimune Group, Inc.
Total debt $127.19M Interest coverage -35.93x This is the baseline the peer rows are being compared against.
Total debt $1.29M Interest coverage -11.04x Neither company has much profit cushion over interest right now.
Total debt $3.59M Interest coverage -8.11x Neither company has much profit cushion over interest right now.
Total debt $31.99M Interest coverage -19.77x Neither company has much profit cushion over interest right now.
Total debt $30.66M Interest coverage -11.20x Neither company has much profit cushion over interest right now.
Total debt $40.11M Interest coverage 78,282.00x This peer still has a real interest-payment cushion, while REPL does not.
What you should know
The case for and against REPL
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -115.8% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-29.93x
P/B
9.30x
P/S
—
EV/EBITDA
-6.78x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-115.8%
ROA
-43.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.62x
Current ratio
7.11x
Quick ratio
6.76x
Total debt
$127.19M
Total cash
$307.83M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-2.79
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-245.55M
Free CF TTM
$-284.57M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—